{
    "clinical_study": {
        "@rank": "114411", 
        "arm_group": [
            {
                "arm_group_label": "Fixed Dose Combination (FDC)", 
                "arm_group_type": "Experimental", 
                "description": "12.5 mg Empagliflozin / 500mg metformin fixed dose combination"
            }, 
            {
                "arm_group_label": "Separate tablets", 
                "arm_group_type": "Active Comparator", 
                "description": "Empagliflozin and Metformin tablets"
            }
        ], 
        "brief_summary": {
            "textblock": "The trial is being conducted to establish the bioequivalence of emp/met (12.5mg/500mg) fixed\n      dose combination tablets compared to tablets administered together in healthy male and\n      female volunteers under fed conditions."
        }, 
        "brief_title": "Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Healthy males or females according to the investigator's assessment, as based on the\n             following criteria: a complete medical history including a physical examination,\n             vital signs (BP, PR), 12-lead ECG and clinical laboratory tests.\n\n          2. Age 18 to 50 years (inclusive)\n\n          3. BMI 18.5 to 29.9 kg/m2 (inclusive)\n\n          4. Signed and dated written informed consent prior to admission to the study in\n             accordance with Good Clinical Practice (GCP) and local legislation.\n\n        Exclusion criteria:\n\n          1. Any finding in the medical examination (Including blood pressure [BP], pulse rate\n             [PR], or electrocardiogram [ECG]) deviating from normal and judged clinically\n             relevant by the investigator.\n\n          2. Any evidence of a concomitant disease judged clinically relevant by the investigator.\n\n          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,\n             immunological or hormonal disorders.\n\n          4. Surgery of the gastrointestinal tract that could interfere with kinetics of the study\n             drug(s)\n\n          5. Diseases of the central nervous system (such as epilepsy), other neurological\n             disorders or psychiatric disorders.\n\n          6. History of relevant orthostatic hypotension, fainting spells, or blackouts.\n\n          7. Chronic or relevant acute infections\n\n          8. History of relevant allergy/hypersensitivity (including allergy to the trial\n             medication or it's excipients)\n\n          9. Intake of drugs with a long half-life (>24 hours) within 30 days or less than 10\n             half-lives of the respective drug prior to administration of trial medication.\n\n         10. Within 14 days prior to the administration of trial medication, use of drugs that\n             might reasonably influence the results of the trial, based on current knowledge\n\n         11. Participation in another trial with investigational drug administration within 60\n             days prior to administration of trial medication.\n\n         12. Smoker (has used tobacco or nicotine-containing products within 6 months prior to\n             administration of trial medication)\n\n         13. Inability to refrain from smoking on specified trial days\n\n         14. Alcohol abuse (consumption of more than 20g/day in females and 30g/day in males or >\n             7 alcohol-containing drinks per week)\n\n         15. Drug abuse or positive drug screen\n\n         16. Blood donation (more than 100 ml wihtin 30 days prior to administration of trial\n             medication or intended during the trial)\n\n         17. Intention to perform excessive physical activities within one week prior to\n             administration of trial medication or during the trial\n\n         18. Inability to comply with dietary regimen of trial site\n\n         19. Subject is assessed by the investigator as unsuitable for inclusion, for instance,\n             because considered not able to understand and comply with study requirements, or has\n             a condition that would not allow safe participation in the study.\n\n             For female subjects:\n\n         20. Positive pregnancy test, pregnancy or plans to become pregnant within 30 days after\n             study completion.\n\n         21. No adequate contraception during the study and until 1 month after study completion,\n             i.e. not any of the following: implants, injectables, combined oral contraceptives,\n             IUD (intrauterine device), sexual abstinence for at least 1 month prior to enrolment,\n             vasectomised partner (vasectomy performed at least 1 year prior to enrolment), or\n             surgical sterilisation (including hysterectomy). Females, who do not have a\n             vasectomised partner, are not sexually abstinent, surgically sterile, or post\n             menopausal will be asked to use an additional barrier method (e.g. condom, diaphragm\n             with spermicide). Post-menopausal is defined as at least 1 year of spontaneous\n             amenorrhea and deemed post menopausal by a physician based on screening clinical\n             laboratory tests (follicle stimulating hormone and luteinizing hormone).\n\n         22. Lactation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02028767", 
            "org_study_id": "1276.24"
        }, 
        "intervention": [
            {
                "arm_group_label": "Separate tablets", 
                "description": "Empagliflozin 2.5 mg tablet", 
                "intervention_name": "Empagliflozin 2.5 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Separate tablets", 
                "description": "Empagliflozin 10 mg tablet", 
                "intervention_name": "Empagliflozin 10 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Separate tablets", 
                "description": "Metformin 500 mg tablet", 
                "intervention_name": "Metformin 500 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Fixed Dose Combination (FDC)", 
                "description": "12.5 mg Empagliflozin / 500 mg Metformin", 
                "intervention_name": "Empagliflozin/Metformin FDC", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "lastchanged_date": "March 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario"
                }, 
                "name": "1276.24.001 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Bioequivalence of Empagliflozin/Metformin (12.5mg/500mg) Fixed Dose Combination Tablets Compared to Tablets Administered Together in Healthy Male and Female Volunteers Under Fed Conditions (an Open Label, Randomised, Single Dose, Two Period, Two Sequence Crossover Study)", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Health Canada"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC 0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 days"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 4 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02028767"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "AUC 0-infinity (Area under the concentration-time curve of he analyte in plasma over the time interval from 0 extrapolated to infinity)", 
            "safety_issue": "No", 
            "time_frame": "up to 4 days"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}